186 related articles for article (PubMed ID: 18448326)
1. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
Hamberg P; Verhagen PC; de Wit R
Eur J Cancer; 2008 Jun; 44(9):1193-7. PubMed ID: 18448326
[TBL] [Abstract][Full Text] [Related]
2. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
3. Hormone-refractory prostate cancer: what have we learned?
Wirth MP
BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
[No Abstract] [Full Text] [Related]
4. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
[TBL] [Abstract][Full Text] [Related]
5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
6. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Mancuso A; Oudard S; Sternberg CN
Crit Rev Oncol Hematol; 2007 Feb; 61(2):176-85. PubMed ID: 17074501
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
9. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in hormone-refractory prostate cancer.
de Wit R
BJU Int; 2008 Mar; 101 Suppl 2():11-5. PubMed ID: 18307687
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
12. [Longer life in hormone refractory prostatic carcinoma].
Krankenpfl J; 2005; 43(4-6):140-1. PubMed ID: 16173125
[No Abstract] [Full Text] [Related]
13. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
17. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
[TBL] [Abstract][Full Text] [Related]
19. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Vogelzang NJ
Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-2. PubMed ID: 10604260
[No Abstract] [Full Text] [Related]
[Next] [New Search]
